Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824561 | 0.73 | GCGR (0.35) | MAPTRAB9AHTTCYP1A2CYP3A4 | |
| SCHEMBL3584758 | 0.70 | CYP1A2 (0.51) | MAPTRAB9AHTTCYP1A2CYP3A4 | |
| SCHEMBL6824369 | 0.69 | GCGR (0.35) | MAPTCYP3A4LMNAALDH1A1PTGES | |
| SCHEMBL6825138 | 0.69 | HPGD (0.50) | MAPTRAB9AHTTCYP1A2CYP2C9 | |
| SCHEMBL16509646 | 0.65 | CYP3A4 (0.58) | MAPTCYP3A4SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1989883 | 0.65 | LMNA (0.56) | MAPTRAB9AHTTCYP1A2CYP2C9 | |
| SCHEMBL68410 | 0.64 | SMN1; SMN2 (0.71) | MAPTCYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL6024215 | 0.64 | ALDH1A1 (0.50) | MAPTRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL2662880 | 0.63 | CA12 (0.62) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL5750124 | 0.63 | L3MBTL1 (0.47) | NPSR1PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737429-B2 | TREATMENT OF HIV MEDIATED DISEASES. | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | MAPT 913/4885RAB9A 1540/4885HTT 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.